Adial Pharmaceuticals, Inc. Recovery of Direct Costs
Adial Pharmaceuticals, Inc. (ADIL) reported Recovery of Direct Costs of $138.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RecoveryOfDirectCosts · last filed 2026-03-05
- Adial Pharmaceuticals, Inc. recovery of direct costs for fiscal 2025 was $138.00K, a 15.34% decline from fiscal 2024.
- Adial Pharmaceuticals, Inc. recovery of direct costs for fiscal 2024 was $163.00K.
| Period end | Recovery of Direct Costs 12 month |
|---|---|
| 2025-12-31 | $138.00K 10-K · filed 2026-03-05 |
| 2024-12-31 | $163.00K 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |